# Massimo Group: financial statements, quarterly

MAMO · Nasdaq · CIK 1952853 · [Industrials](/sectors/industrials.md)

Pages: [Overview](/companies/mamo.md) · [Financials](/companies/mamo/financials.md) · [Filings](/companies/mamo/filings.md) · [Insiders](/companies/mamo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mamo/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.9](/filings/0001493152-24-045987.md) | [39.6 d](/filings/0001641172-25-011711.md) | [30.2](/filings/0001641172-25-011725.md) | [35.4](/filings/0001493152-25-011970.md) | [25.6](/filings/0001493152-25-021309.md) | [18.2 d](/filings/0001493152-26-013862.md) | [14.9](/filings/0001493152-26-023439.md) | [18.9](/filings/0001493152-26-037802.md) | [17.0](/filings/0001493152-25-021309.md) | [21.0 d](/filings/0001493152-26-013862.md) | [12.7](/filings/0001493152-26-023439.md) | [14.9](/filings/0001493152-26-037802.md) |
| Cost of revenue | $m | [19.9](/filings/0001493152-24-045987.md) | [27.4 d](/filings/0001641172-25-011711.md) | [19.7](/filings/0001641172-25-011725.md) | [23.9](/filings/0001493152-25-011970.md) | [18.6](/filings/0001493152-25-021309.md) | [14.6 d](/filings/0001493152-26-013862.md) | [10.7](/filings/0001493152-26-023439.md) | [12.0](/filings/0001493152-26-037802.md) | [9.9](/filings/0001493152-25-021309.md) | [12.3 d](/filings/0001493152-26-013862.md) | [7.6](/filings/0001493152-26-023439.md) | [7.6](/filings/0001493152-26-037802.md) |
| Gross profit | $m | [10.1](/filings/0001493152-24-045987.md) | [12.1 d](/filings/0001641172-25-011711.md) | [10.5](/filings/0001641172-25-011725.md) | [11.5](/filings/0001493152-25-011970.md) | [7.0](/filings/0001493152-25-021309.md) | [3.6 d](/filings/0001493152-26-013862.md) | [4.2](/filings/0001493152-26-023439.md) | [6.9](/filings/0001493152-26-037802.md) | [7.1](/filings/0001493152-25-021309.md) | [8.7 d](/filings/0001493152-26-013862.md) | [5.1](/filings/0001493152-26-023439.md) | [7.3](/filings/0001493152-26-037802.md) |
| Research and development | $m | not reported | not reported | [0.2](/filings/0001641172-25-011725.md) | [0.0 d](/filings/0001493152-25-011970.md) | [0.1](/filings/0001493152-25-021309.md) | [0.1 d](/filings/0001493152-26-013862.md) | [0.8](/filings/0001493152-26-023439.md) | [0.1](/filings/0001493152-26-037802.md) | [0.8](/filings/0001493152-25-021309.md) | [0.3 d](/filings/0001493152-26-013862.md) | [0.6](/filings/0001493152-26-023439.md) | [0.3](/filings/0001493152-26-037802.md) |
| Operating income | $m | [5.2](/filings/0001493152-24-045987.md) | [4.7 d](/filings/0001641172-25-011711.md) | [4.0](/filings/0001641172-25-011725.md) | [3.6](/filings/0001493152-25-011970.md) | [0.3](/filings/0001493152-25-021309.md) | [(2.8) d](/filings/0001493152-26-013862.md) | [(2.7)](/filings/0001493152-26-023439.md) | [0.1](/filings/0001493152-26-037802.md) | [1.8](/filings/0001493152-25-021309.md) | [2.8 d](/filings/0001493152-26-013862.md) | [(1.0)](/filings/0001493152-26-023439.md) | [1.7](/filings/0001493152-26-037802.md) |
| Interest expense | $m | [0.2](/filings/0001493152-24-045987.md) | [0.0 d](/filings/0001493152-24-014560.md) | [0.1](/filings/0001493152-24-018997.md) | [0.1](/filings/0001493152-25-011970.md) | [0.1](/filings/0001493152-25-021309.md) | [(0.2) d](/filings/0001493152-26-013862.md) | [0.0](/filings/0001493152-26-023439.md) | [0.1](/filings/0001493152-26-037802.md) | [(0.0)](/filings/0001493152-25-021309.md) | [(0.0) d](/filings/0001493152-26-013862.md) | [0.0](/filings/0001493152-26-023439.md) | [0.0](/filings/0001493152-26-037802.md) |
| Income tax | $m | [1.1](/filings/0001493152-24-045987.md) | [0.9 d](/filings/0001641172-25-011711.md) | [0.9](/filings/0001641172-25-011725.md) | [0.8](/filings/0001493152-25-011970.md) | [(0.6)](/filings/0001493152-25-021309.md) | [(0.4) d](/filings/0001493152-26-013862.md) | [(0.5)](/filings/0001493152-26-023439.md) | [0.0](/filings/0001493152-26-037802.md) | [0.4](/filings/0001493152-25-021309.md) | [0.6 d](/filings/0001493152-26-013862.md) | [(0.2)](/filings/0001493152-26-023439.md) | [0.3](/filings/0001493152-26-037802.md) |
| Net income | $m | [4.0](/filings/0001493152-24-045987.md) | [3.8 d](/filings/0001641172-25-011711.md) | [3.2](/filings/0001641172-25-011725.md) | [2.8](/filings/0001493152-25-011970.md) | [(2.5)](/filings/0001493152-25-021309.md) | [(1.7) d](/filings/0001493152-26-013862.md) | [(2.1)](/filings/0001493152-26-023439.md) | [0.1](/filings/0001493152-26-037802.md) | [1.5](/filings/0001493152-25-021309.md) | [2.0 d](/filings/0001493152-26-013862.md) | [(1.0)](/filings/0001493152-26-023439.md) | [1.5](/filings/0001493152-26-037802.md) |
| Diluted EPS | $ per share | [0.10](/filings/0001493152-24-045987.md) | not reported | [0.08](/filings/0001641172-25-011725.md) | [0.07](/filings/0001493152-25-011970.md) | [(0.06)](/filings/0001493152-25-021309.md) | not reported | [(0.05)](/filings/0001493152-26-023439.md) | [0.00](/filings/0001493152-25-011970.md) | [0.04](/filings/0001493152-25-021309.md) | not reported | [(0.02)](/filings/0001493152-26-023439.md) | [0.03](/filings/0001493152-26-037802.md) |
| Basic EPS | $ per share | [0.10](/filings/0001493152-24-045987.md) | not reported | [0.08](/filings/0001641172-25-011725.md) | [0.07](/filings/0001493152-25-011970.md) | [(0.06)](/filings/0001493152-25-021309.md) | not reported | [(0.05)](/filings/0001493152-26-023439.md) | [0.00](/filings/0001493152-25-011970.md) | [0.04](/filings/0001493152-25-021309.md) | not reported | [(0.02)](/filings/0001493152-26-023439.md) | [0.03](/filings/0001493152-26-037802.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [10.2](/filings/0001493152-26-013862.md) | not reported | not reported | [2.6](/filings/0001493152-25-021309.md) | [5.8](/filings/0001493152-26-037802.md) | [4.1](/filings/0001493152-26-023439.md) | [4.6](/filings/0001493152-26-037802.md) |
| Current assets | $m | not reported | [38.4](/filings/0001641172-25-011711.md) | [43.7](/filings/0001493152-24-018997.md) | [45.2](/filings/0001493152-24-031164.md) | [45.1](/filings/0001493152-24-045987.md) | [43.6](/filings/0001493152-26-013862.md) | [35.1](/filings/0001641172-25-011725.md) | [35.3](/filings/0001493152-25-011970.md) | [34.6](/filings/0001493152-25-021309.md) | [39.8](/filings/0001493152-26-037802.md) | [32.9](/filings/0001493152-26-023439.md) | [37.3](/filings/0001493152-26-037802.md) |
| Total assets | $m | not reported | [41.9](/filings/0001641172-25-011711.md) | [47.3](/filings/0001493152-24-018997.md) | [49.9](/filings/0001493152-24-031164.md) | [57.1](/filings/0001493152-24-045987.md) | [54.9](/filings/0001493152-26-013862.md) | [46.4](/filings/0001641172-25-011725.md) | [45.9](/filings/0001493152-25-011970.md) | [44.4](/filings/0001493152-25-021309.md) | [51.4](/filings/0001493152-26-037802.md) | [44.3](/filings/0001493152-26-023439.md) | [48.7](/filings/0001493152-26-037802.md) |
| Current liabilities | $m | not reported | [18.8](/filings/0001641172-25-011711.md) | [20.6](/filings/0001493152-24-018997.md) | [18.1](/filings/0001493152-24-031164.md) | [26.3](/filings/0001493152-24-045987.md) | [25.7](/filings/0001493152-26-013862.md) | [19.6](/filings/0001641172-25-011725.md) | [19.4](/filings/0001493152-25-011970.md) | [16.7](/filings/0001493152-25-021309.md) | [22.3](/filings/0001493152-26-037802.md) | [16.6](/filings/0001493152-26-023439.md) | [20.1](/filings/0001493152-26-037802.md) |
| Total liabilities | $m | not reported | [27.5](/filings/0001641172-25-011711.md) | [29.1](/filings/0001493152-24-018997.md) | [25.1](/filings/0001493152-24-031164.md) | [34.5](/filings/0001493152-24-045987.md) | [33.2](/filings/0001493152-26-013862.md) | [26.4](/filings/0001641172-25-011725.md) | [25.8](/filings/0001493152-25-011970.md) | [22.7](/filings/0001493152-25-021309.md) | [27.7](/filings/0001493152-26-037802.md) | [21.6](/filings/0001493152-26-023439.md) | [24.6](/filings/0001493152-26-037802.md) |
| Short-term borrowings | $m | not reported | [0.3](/filings/0001641172-25-011711.md) | not reported | [2.7](/filings/0001493152-24-031164.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [10.4](/filings/0001493152-24-045987.md) | [14.5](/filings/0001493152-26-013862.md) | [18.1](/filings/0001493152-25-011970.md) | [24.7](/filings/0001493152-25-021309.md) | [22.5](/filings/0001493152-25-021309.md) | [21.7](/filings/0001493152-26-037802.md) | [19.9](/filings/0001493152-26-037802.md) | [20.2](/filings/0001493152-26-037802.md) | [21.7](/filings/0001493152-25-021309.md) | [23.7](/filings/0001493152-26-037802.md) | [22.7](/filings/0001493152-26-037802.md) | [24.1](/filings/0001493152-26-037802.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [3,040 d](/filings/0001493152-24-045987.md) | [5,127 d](/filings/0001641172-25-011711.md) | [(637)](/filings/0001641172-25-011725.md) | [(6,472) d](/filings/0001493152-25-011970.md) | [4,712 d](/filings/0001493152-25-021309.md) | [9,069 d](/filings/0001493152-26-013862.md) | [(3,339)](/filings/0001493152-26-023439.md) | [(1,392) d](/filings/0001493152-26-037802.md) | [633 d](/filings/0001493152-25-021309.md) | [4,000 d](/filings/0001493152-26-013862.md) | [(1,377)](/filings/0001493152-26-023439.md) | [1,308 d](/filings/0001493152-26-037802.md) |
| Capital expenditure | $k | [44.2](/filings/0001493152-24-045987.md) | [65.8 d](/filings/0001641172-25-011711.md) | [104](/filings/0001641172-25-011725.md) | [237](/filings/0001493152-24-031164.md) | [82.3](/filings/0001493152-24-045987.md) | [(36.3) d](/filings/0001493152-26-013862.md) | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-013862.md) | [262](/filings/0001493152-26-023439.md) | [406](/filings/0001493152-26-037802.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.0](/filings/0001493152-24-018997.md) | [40.0](/filings/0001493152-24-031164.md) | [40.0](/filings/0001493152-24-045987.md) | [40.0](/filings/0001641172-25-011725.md) | [41.4](/filings/0001493152-25-011970.md) | [41.3](/filings/0001493152-25-021309.md) | [41.5](/filings/0001493152-26-023439.md) | [41.6](/filings/0001493152-26-037802.md) | [41.6](/filings/0001493152-25-021309.md) | [41.6](/filings/0001493152-26-023439.md) | [41.6](/filings/0001493152-26-037802.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,640,950 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037802.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.